When did Bio-Rad Laboratories, Inc. report Q4 2024 earnings?

Bio-Rad Laboratories, Inc. (BIO.B) reported Q4 2024 earnings on February 13, 2025 before market open.

What were Bio-Rad Laboratories, Inc.'s Q4 2024 revenue and EPS?

Bio-Rad Laboratories, Inc. reported revenue of $667.5M and diluted EPS of $-25.57 for Q4 2024.

Did Bio-Rad Laboratories, Inc. beat estimates in Q4 2024?

Revenue missed the consensus estimate of $679.8M by $12.3M. EPS missed the consensus estimate of $2.86 by $28.43.

Where can I find Bio-Rad Laboratories, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0000012208-25-000007) directly on SEC EDGAR. The filing index links above go to sec.gov.

Bio-Rad Laboratories, Inc. BIO.B Q4 2024 Annual earnings

Reported February 13, 2025 · Before market open

Revenue$667.5MMiss by $12.3M Diluted EPS-$25.57Miss by $28.43

Revenue estimate$679.8M

EPS estimate$2.86

Next report

Jul 30, 2026 (in a month)

Revenue estimate$624.8M

EPS estimate$1.78

Financials

Q4 2024

Income statement

See full

Revenue$667.5M-2.0%

Gross profit$342.0M-6.6%

Operating income$58.3M-38.8%

Net income-$715.8M-305%

EPS (diluted)-$25.57-311%

Balance sheet

See full

Cash & equivalents$489.8M+21.1%

Total debt$1.4B-2.3%

Total equity$6.6B-24.8%

Total assets$9.4B-23.9%

Cash flow

See full

Operating cash flow$124.2M+53.3%

CapEx$42.9M+1.5%

Free cash flow$81.3M+110%

Valuation & ratios

Q4 2024

Valuation

See full

Market cap$9.2B-2.3%

Enterprise value$10.09B-3.2%

P/S3.6×+0.1×

Profitability

See full

Gross margin53.7%+0.3pp

Operating margin10.5%-2.2pp

Net margin-71.9%-143pp

FCF margin11.3%+3.1pp

Returns & leverage

See full

Return on equity-24.1%-40.5pp

Debt / equity0.2×0.0×

Current ratio6.5×+0.6×

Segments

By segment

See full

Clinical Diagnostics$392.5M+0.9%

Life Science$275.0M-5.5%

All Other Segments$125.0K-85.7%

By geography

See full

Europe$221.7M+5.2%

Asia Pacific$146.4M-10.8%

Americas$41.3M-4.4%

Versus estimates

Revenue

Q1 2026$592.1MBeat by $784.1K Q4 2025$693.2MBeat by $5.2M Q3 2025$653.0MBeat by $1.5M Q2 2025$651.6MMiss by $55.0M Q1 2025$585.4MBeat by $12.2M

Q4 2024$667.5MMiss by $12.3M

Diluted EPS

Q1 2026$1.89Miss by $0.12 Q4 2025$2.51Miss by $0.18 Q3 2025-$12.70Miss by $14.59 Q2 2025$11.67Beat by $9.92 Q1 2025$2.29Beat by $0.47

Q4 2024-$25.57Miss by $28.43

Ask the moment Bio-Rad Laboratories, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Bio-Rad Laboratories, Inc. report Q4 2024 earnings?: Bio-Rad Laboratories, Inc. (BIO.B) reported Q4 2024 earnings on February 13, 2025 before market open.
What were Bio-Rad Laboratories, Inc.'s Q4 2024 revenue and EPS?: Bio-Rad Laboratories, Inc. reported revenue of $667.5M and diluted EPS of $-25.57 for Q4 2024.
Did Bio-Rad Laboratories, Inc. beat estimates in Q4 2024?: Revenue missed the consensus estimate of $679.8M by $12.3M. EPS missed the consensus estimate of $2.86 by $28.43.
Where can I find Bio-Rad Laboratories, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0000012208-25-000007) directly on SEC EDGAR. The filing index links above go to sec.gov.